...plc (LSE:GSK; NYSE:GSK); and Daniel Spiegelman, who most recently served as EVP and CFO at BioMarin Pharmaceutical Inc....

...for hemophilia A therapy valoctocogene roxaparvovec from BioMarin...

...the approved dose without any increases in the frequency of known adverse events for the class.BioMarin...
...platform to identify oligonucleotide therapies in four undisclosed rare disease indiccations; financial terms are undisclosed. BioMarin...

...of opinions was an MAA withdrawal for BioMarin’s...
...the safety profile of Roctavian valoctocogene roxaparvovec from BioMarin Pharmaceutical Inc....
...Factor VIII to treat severe hemophilia A, BioMarin...

...By Paul Bonanos, Associate Editor Although BioMarin’s NDA for its achondroplasia treatment doesn’t quite match up...
...date of Aug. 20, 2021.FDA’s action removes some uncertainty as to whether the dataset from BioMarin Pharmaceutical Inc....
...refusal-to-file letter was possible. The therapy received standard review to treat achondroplasia, a form of dwarfism.BioMarin...

...One-year follow up for giroctocogene fitelparvovec will occur around the same time as BioMarin’s two-year follow-up...
...12 months, it could put the partners very close to the timing of key competitor BioMarin...
...after, Pfizer Inc. (NYSE:PFE) and Sangamo Therapeutics Inc. (NASDAQ:SGMO) could be neck and neck with BioMarin Pharmaceutical Inc....

...promotes Nestle to head of research, CSO; Eggan joins BioMarin By Paul Bonanos, Associate Editor BioMarin...
...the French pharma has promoted from within to replace two executives who are leaving the company.BioMarin...
...Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard.In recent years, BioMarin...

...BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) the hardest hit down 38%, closing the quarter at a $13.8 billion valuation. BioMarin...

...Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG); and Roctavian valoctocogene roxaparvovec, a hemophilia A gene therapy from BioMarin Pharmaceutical Inc....

...Collecting two-year data will set BioMarin back at least 15 months, but it still has a...
...to market first By  Sandi Wong, Assistant Editor FDA has moved the goal post for BioMarin’s Roctavian...
...candidate could still be the first gene therapy to win approval for hemophilia A.Shares of BioMarin Pharmaceutical Inc....